耐斯系统 NICE 深 沪
已收盘 06-12 16:00:00 美东时间
88.71
+0.630
+0.72%
华盛通- 最 高88.97
- 今 开87.24
- 成交量 73.53万股
- 最 低 85.80
- 昨 收 88.08
- 总市值 526.97万
- 52周最高 175.00
- 市盈率 静 9.10
- 换手率 1237.84%
- 52周最低 84.3825
- 委 比 -21.88%
- 总股本 5.94万
- 历史最高 319.88
- 量 比 0.88
- 振 幅 3.60%
- 历史最低 25.855
- 每 手 1
- 风险率 22.58%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 高盛上调美光科技目标价从400美元升至900美元；斯马克、Cloudflare获多家公司上调目标价
今日重点评级关注：Ascendiant Capital：维持NextTrip"买入"评级，目标价从7美元升至7.5美元；Maxim Group：维持Zevra Therapeutics"买入"评级，目标价从25美元升至35美元
06-11 09:55
Cantor Fitzgerald Reiterates Neutral on NICE, Maintains $104 Price Target
Cantor Fitzgerald analyst Thomas Blakey reiterates NICE (NASDAQ:NICE) with a Neutral and maintains $104 price target.
06-10 21:17
BluIP and NiCE Deliver Enterprise-Wide Intelligence with Unified UCaaS + CCaaS Solution
Integrated Cloud PBX and Contact Center Platform Extends AI, Analytics, and Operational Intelligence Across the Entire Organization LAS VEGAS, June 8, 2026 /PRNewswire/ -- BluIP, a leading p...
06-09 01:52
Shares of software companies are trading higher following Nvidia's introduction of AI tools for industries including autonomous driving, humanoid robots and AI factories that may be seen as a tailwind for the broader sector.
Shares of software companies are trading higher following Nvidia's introduction...
06-02 00:44
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
美股大行评级 | 爱彼迎、Affirm、CoreWeave、Datadog、微芯科技等获多家大行上调目标价；HubSpot惨遭14家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从15美元升至35美元；韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从36美元升至37美元
05-11 15:43
美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
Citizens Maintains Market Outperform on NICE, Lowers Price Target to $170
Citizens analyst Patrick Walravens maintains NICE (NASDAQ:NICE) with a Market Outperform and lowers the price target from $200 to $170.
05-08 00:44
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
NICE shares are trading lower. The company reported Q1 financial results.
NICE shares are trading lower. The company reported Q1 financial results.
05-06 22:42
